Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant radiotherapy for locally advanced and high-risk breast cancer.
Chidley P, Foroudi F, Tacey M, Khor R, Yeh J, Bevington E, Hyett A, Loh SW, Chew G, McCracken J, Neoh D, Yeo B, Baker C, Jassal S, Law M, Zantuck N, Cokelek M, Guerrieri M, Brown B, Stoney D, Ng M, Chao M. Chidley P, et al. Among authors: yeo b. J Med Imaging Radiat Oncol. 2021 Jun;65(3):345-353. doi: 10.1111/1754-9485.13180. Epub 2021 Apr 5. J Med Imaging Radiat Oncol. 2021. PMID: 33821576 Review.
Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial.
Ramchand SK, Ghasem-Zadeh A, Hoermann R, White S, Yeo B, Francis PA, Xu CLH, Coleman O, Shore-Lorenti C, Ebeling PR, Zajac JD, Seeman E, Grossmann M. Ramchand SK, et al. Among authors: yeo b. J Clin Oncol. 2024 Jul 2:JCO2302309. doi: 10.1200/JCO.23.02309. Online ahead of print. J Clin Oncol. 2024. PMID: 38954783
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Lopez-Knowles E, Pearson A, Schuster G, Gellert P, Ribas R, Yeo B, Cutts R, Buus R, Garcia-Murillas I, Haynes B, Martin LA, Smith I, Turner N, Dowsett M. Lopez-Knowles E, et al. Among authors: yeo b. Br J Cancer. 2019 Jan;120(2):247-255. doi: 10.1038/s41416-018-0345-x. Epub 2018 Dec 19. Br J Cancer. 2019. PMID: 30563991 Free PMC article.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
422 results